Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marc Rothenberg

Pediatric Allergy/Immunology Cincinnati, OH Medical Doctor

NPI 1760431233 CMS profile 498995

3333 Burnet Ave, Mlc 2000, Cincinnati, OH 45229

Open in the dashboard

General payments

$125,516

77 records reported · program years 2019–2025

Research payments

$74,623

Paid to them · 138 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,789,288 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Marc Rothenberg of Cincinnati, OH is reported in the CMS Open Payments database as having received $125,516 across 77 general payments and $74,623 in research payments paid to them. Separately, studies naming them as principal investigator received $9,789,288 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Pediatric Allergy/Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $93 1
2025 Research $7,203 4
2024 General $16,348 16
2024 Research $16,995 28
2023 General $9,605 7
2023 Research $21,422 36
2022 General $5,932 4
2022 Research $11,892 27
2021 General $14,000 10
2021 Research $8,013 21
2020 General $55,314 27
2020 Research $4,194 19
2019 General $24,225 12
2019 Research $4,904 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Rothenberg
  • Pediatric Allergy/Immunology median
  • Middle half of Pediatric Allergy/Immunology
  • National median

In program year 2025, general payments to Marc Rothenberg were reported at $93. Among 289 Pediatric Allergy/Immunology profiles paid that year, the median was $361 and the middle half received between $125 and $2,493.

Show as a table
Year Marc Rothenberg Pediatric Allergy/Immunology median Middle half National median
2019 $24,225 $325 $92–$1,399 $163
2020 $55,314 $144 $66–$2,490 $114
2021 $14,000 $357 $95–$2,633 $132
2022 $5,932 $385 $125–$2,259 $149
2023 $9,605 $470 $121–$2,946 $160
2024 $16,348 $317 $125–$2,583 $164
2025 $93 $361 $125–$2,493 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca UK Limited $38,451 17 payments
  2. Celgene Corporation $20,880 6 payments
  3. GlaxoSmithKline, LLC. $11,793 7 payments
  4. E.R. Squibb & Sons, L.L.C. $11,630 5 payments
  5. AstraZeneca Pharmaceuticals LP $10,731 16 payments
  6. Genzyme Corporation $8,387 4 payments
  7. AstraZeneca AB $6,432 5 payments
  8. Regeneron Pharmaceuticals, Inc. $5,576 10 payments
  9. Sanofi-Aventis U.S. LLC $3,983 1 payment
  10. Takeda Pharmaceuticals U.S.A., Inc. $2,880 1 payment
  11. Other $4,773 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $119,185 58 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,233 2 payments
  3. Travel and Lodging $1,398 7 payments
  4. Food and Beverage $701 10 payments
Products named General payments · program years 2019–2025
  1. FASENRA Respiratory $37,433 23 payments
  2. DUPIXENT Immunology $12,370 5 payments
  3. Ozanimod $11,340 3 payments
  4. FASENRA Respiratory $7,358 6 payments
  5. ZEPOSIA $7,200 2 payments
  6. DUPIXENT Inflammation And Immunology $5,624 11 payments
  7. NUCALA Respiratory $3,250 1 payment
  8. TEZSPIRE $2,589 3 payments
  9. NUCALA Immunology $1,300 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $71,757 137 payments
  2. Celgene Corporation $2,866 1 payment

Records

215 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Allergy/Immunology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record